Beam optics study for a potential VHEE beam delivery system
Journal of Physics: Conference Series IOP Publishing 2420:1 (2023)
Abstract:
VHEE (Very High Energy Electron) therapy can be superior to conventional radiotherapy for the treatment of deep seated tumours, whilst not necessarily requiring the space and cost of proton or heavy ion facilities. Developments in high gradient RF technology have allowed electrons to be accelerated to VHEE energies in a compact space, meaning that treatment could be possible with a shorter linac. A crucial component of VHEE treatment is the transfer of the beam from accelerator to patient. This is required to magnify the beam to cover the transverse extent of the tumour, whilst ensuring a uniform beam distribution. Two principle methodologies for the design of a compact transfer line are presented. The first of these is based upon a quadrupole lattice and optical magnification of beam size. A minimisation algorithm is used to enforce certain criteria on the beam distribution at the patient, defining the lattice through an automated routine. Separately, a dual scattering-foil based system is also presented, which uses similar algorithms for the optimisation of the foil geometry in order to achieve the desired beam shape at the patient location.Collaboration: The Force That Makes the Impossible Possible.
Advances in radiation oncology 7:6 (2022) 100966
Abstract:
Over the last three decades, the landscape of cancer treatment with radiotherapy has never stopped improving. ENLIGHT - the European Network for Light Ion Hadron Therapy - has been an active participant in the huge changes that have taken place, in particular in Europe. At the end of the 90s when I arrived at CERN, it appeared clear that an improvement in communication, sharing and exchange, while keeping a common goal, was needed to bring together international experts from accelerator physics, imaging, medical physics, radiobiology and clinical medicine. ENLIGHT network was most aptly launched at CERN, since CERN is renowned as a place for global collaboration. The network has come a long way since the kick-off meeting at CERN in 2002 when only about 70 specialists from different disciplines took part and continues to grow and flourish with now over 1000 participants, accounting for over 100 institutions, from around 40 countries around the globe.Clinical use and future requirements of relative biological effectiveness: Survey among all European proton therapy centres.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 172 (2022) 134-139
Abstract:
Background and purpose
The relative biological effectiveness (RBE) varies along the treatment field. However, in clinical practice, a constant RBE of 1.1 is assumed, which can result in undesirable side effects. This study provides an accurate overview of current clinical practice for considering proton RBE in Europe.Materials and methods
A survey was devised and sent to all proton therapy centres in Europe that treat patients. The online questionnaire consisted of 39 questions addressing various aspects of RBE consideration in clinical practice, including treatment planning, patient follow-up and future demands.Results
All 25 proton therapy centres responded. All centres prescribed a constant RBE of 1.1, but also applied measures (except for one eye treatment centre) to counteract variable RBE effects such as avoiding beams stopping inside or in front of an organ at risk and putting restrictions on the minimum number and opening angle of incident beams for certain treatment sites. For the future, most centres (16) asked for more retrospective or prospective outcome studies investigating the potential effect of the effect of a variable RBE. To perform such studies, 18 centres asked for LET and RBE calculation and visualisation tools developed by treatment planning system vendors.Conclusion
All European proton centres are aware of RBE variability but comply with current guidelines of prescribing a constant RBE. However, they actively mitigate uncertainty and risk of side effects resulting from increased RBE by applying measures and restrictions during treatment planning. To change RBE-related clinical guidelines in the future more clinical data on RBE are explicitly demanded.Availability of technology for managing cancer patients in the Southeast European (SEE) region.
Clinical and translational radiation oncology 34 (2022) 57-66
Abstract:
Background
The Southeast European (SEE) region of 10 countries and about 43 million people differs from Western Europe in that most SEE countries lack active cancer registries and have fewer diagnostic imaging devices and radiotherapy (RT) units. The main objective of this research is to initiate a common platform for gathering SEE regional cancer data from the ground up to help these countries develop common cancer management strategies.Methods
To obtain detailed on-the-ground information, we developed separate questionnaires for two SEE groups: a) ONCO - oncologists regarding cancer treatment modalities and the availability of diagnostic imaging and radiotherapy equipment; and b) REG - national radiation protection and safety regulatory bodies regarding diagnostic imaging and radiotherapy equipment in SEE facilities.Results
Based on responses from 13/17 ONCO participants (at least one from each country) and from 9/10 REG participants (all countries but Albania), cancer incidence rates are higher in those SEE countries that have greater access to diagnostic imaging equipment while cancer mortality-to-incidence (MIR) ratios are higher in countries that lack radiotherapy equipment.Conclusion
By combining unique SEE region information with data available from major global databases, we demonstrated that the availability of diagnostic imaging and radiotherapy equipment in the SEE countries is related to their economic development. While immediate diagnostic imaging and radiation therapy capacity building is necessary, it is also essential to develop both national and SEE-regional cancer registries in order to understand the heterogeneity of each country's needs and to establish regional collaborative strategies for combating cancer.Surveying the Challenges to Improve Linear Accelerator-based Radiation Therapy in Africa: a Unique Collaborative Platform of All 28 African Countries Offering Such Treatment.
Clinical oncology (Royal College of Radiologists (Great Britain)) 33:12 (2021) e521-e529